{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:44:00Z","timestamp":1761237840377},"reference-count":48,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1372,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis & Rheumatism"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1002\/art.30650","type":"journal-article","created":{"date-parts":[[2011,9,28]],"date-time":"2011-09-28T02:33:51Z","timestamp":1317177231000},"page":"3758-3767","source":"Crossref","is-referenced-by-count":13,"title":["Development of a novel recombinant biotherapeutic with applications in targeted therapy of human arthritis"],"prefix":"10.1002","volume":"63","author":[{"given":"Panagiotis","family":"Kamperidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahereh","family":"Kamalati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toby","family":"Garrood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soraya","family":"Diez-Posada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciara","family":"Finucane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Mather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahuva","family":"Nissim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J. T.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Costantino","family":"Pitzalis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,11,29]]},"reference":[{"key":"10.1002\/art.30650-BIB1|cit1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/art.1790080202","article-title":"Awareness of the prevalence and impact of arthritis: the role of health professionals","volume":"8","author":"Callahan","year":"1995","journal-title":"Arthritis Care Res"},{"key":"10.1002\/art.30650-BIB2|cit2","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/rheumatology\/kel253","article-title":"Mortality in rheumatoid arthritis: increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis","volume":"46","author":"Young","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/art.30650-BIB3|cit3","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1186\/ar575","article-title":"Angiogenesis in rheumatoid arthritis","volume":"4","author":"Paleolog","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1002\/art.30650-BIB4|cit4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","article-title":"Cytokine pathways and joint inflammation in rheumatoid arthritis","volume":"344","author":"Choy","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1002\/art.30650-BIB5|cit5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/ar2515","article-title":"Vascular involvement in rheumatic diseases: \u2018vascular rheumatology.\u2019","volume":"10","author":"Szekanecz","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1002\/art.30650-BIB6|cit6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2613.2009.00640.x","article-title":"The vasculature in rheumatoid arthritis: cause or consequence?","volume":"90","author":"Paleolog","year":"2009","journal-title":"Int J Exp Pathol"},{"key":"10.1002\/art.30650-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(98)05912-1","article-title":"Angioneogenesis as a possible elusive triggering factor in rheumatoid arthritis","volume":"353","author":"Hirohata","year":"1999","journal-title":"Lancet"},{"key":"10.1002\/art.30650-BIB8|cit8","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.clim.2007.04.014","article-title":"Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction","volume":"124","author":"Clavel","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1002\/art.30650-BIB9|cit9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10456-007-9081-1","article-title":"Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience","volume":"10","author":"Khong","year":"2007","journal-title":"Angiogenesis"},{"key":"10.1002\/art.30650-BIB10|cit10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/ncprheum0559","article-title":"Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis","volume":"3","author":"Lainer-Carr","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1002\/art.30650-BIB11|cit11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jbspin.2009.05.011","article-title":"New insights in synovial angiogenesis","volume":"77","author":"Szekanecz","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1002\/art.30650-BIB12|cit12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/ncprheum0909","article-title":"Therapeutic advances in rheumatology with the use of recombinant proteins","volume":"4","author":"Rothe","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1002\/art.30650-BIB13|cit13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.7326\/0003-4819-134-8-200104170-00013","article-title":"Rational use of new and existing disease-modifying agents in rheumatoid arthritis","volume":"134","author":"Kremer","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1002\/art.30650-BIB14|cit14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2009.181","article-title":"Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis","volume":"5","author":"Taylor","year":"2009","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl","key":"10.1002\/art.30650-BIB15|cit15","first-page":"25","article-title":"Comparative overview of safety of the biologics in rheumatoid arthritis","volume":"82","author":"Khraishi","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1002\/art.30650-BIB16|cit16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1002\/art.30650-BIB17|cit17","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/rheumatology\/kep117","article-title":"A novel model for the pre-clinical imaging of inflamed human synovial vasculature","volume":"48","author":"Garrood","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1002\/art.30650-BIB18|cit18","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/art.10464","article-title":"Identification of synovium-specific homing peptides by in vivo phage display selection","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30650-BIB19|cit19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0167-7799(03)00079-9","article-title":"Isolating ligands specific for human vasculature using in vivo phage selection","volume":"21","author":"George","year":"2003","journal-title":"Trends Biotechnol"},{"key":"10.1002\/art.30650-BIB20|cit20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2249.2000.01342.x","article-title":"Tumour necrosis factor-alpha (TNF-\u03b1) enhances lymphocyte migration into rheumatoid synovial tissue transplanted into severe combined immunodeficient (SCID) mice","volume":"122","author":"Wahid","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1002\/art.30650-BIB21|cit21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/79494","article-title":"Antibody arrays for high-throughput screening of antibody-antigen interactions","volume":"18","author":"De Wildt","year":"2000","journal-title":"Nat Biotechnol"},{"key":"10.1002\/art.30650-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/art.27346","article-title":"Human single-chain variable fragment that specifically targets arthritic cartilage","volume":"62","author":"Hughes","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30650-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1006\/jmbi.2001.5314","article-title":"Selection of large diversities of antiidiotypic antibody fragments by phage display","volume":"315","author":"Goletz","year":"2002","journal-title":"J Mol Biol"},{"key":"10.1002\/art.30650-BIB24|cit24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0076-6879(96)67007-4","article-title":"Screening of phage antibody libraries","volume":"267","author":"Harrison","year":"1996","journal-title":"Methods Enzymol"},{"key":"10.1002\/art.30650-BIB25|cit25","first-page":"509","article-title":"Optimal quality 131I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN","volume":"42","author":"Visser","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1002\/art.30650-BIB26|cit26","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1017\/S143192761009389X","article-title":"Colocalization analysis in fluorescence micrographs: verification of a more accurate calculation of Pearson's correlation coefficient","volume":"16","author":"Barlow","year":"2010","journal-title":"Microsc Microanal"},{"key":"10.1002\/art.30650-BIB27|cit27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/cyto.a.20896","article-title":"Quantifying colocalization by correlation: the Pearson correlation coefficient is superior to the Mander's overlap coefficient","volume":"77","author":"Adler","year":"2010","journal-title":"Cytometry A"},{"key":"10.1002\/art.30650-BIB28|cit28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/ard.62.4.303","article-title":"Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints","volume":"62","author":"Smith","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/art.30650-BIB29|cit29","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","article-title":"Golimumab, a human anti-tumor necrosis factor \u03b1 monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1002\/art.30650-BIB30|cit30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor \u03b1 given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/art.30650-BIB31|cit31","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrrheum.2009.182","article-title":"Treatment of rheumatoid arthritis: state of the art 2009","volume":"5","author":"Van Vollenhoven","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1002\/art.30650-BIB32|cit32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrrheum.2009.197","article-title":"Are new agents needed to treat RA?","volume":"5","author":"Lipsky","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1002\/art.30650-BIB33|cit33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/BOR.0b013e328337c95a","article-title":"Angiogenesis and vasculogenesis in rheumatoid arthritis","volume":"22","author":"Szekanecz","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1002\/art.30650-BIB34|cit34","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/ar1156","article-title":"Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky","volume":"6","author":"Middleton","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1002\/art.30650-BIB35|cit35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.it.2006.05.005","article-title":"From ubiquitous antigens to joint-specific inflammation: could local vascular permeability be the missing link?","volume":"27","author":"Pitzalis","year":"2006","journal-title":"Trends Immunol"},{"key":"10.1002\/art.30650-BIB36|cit36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-7643-7650-5_7","volume-title":"Angiogenesis in inflammation: mechanisms and clinical correlates","author":"Alam","year":"2008"},{"key":"10.1002\/art.30650-BIB37|cit37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/cmdc.200600181","article-title":"Ligand-based vascular targeting of disease","volume":"2","author":"Rybak","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1002\/art.30650-BIB38|cit38","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1186\/ar2115","article-title":"Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis","volume":"9","author":"Trachsel","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1002\/art.30650-BIB39|cit39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-3-540-78281-0_12","article-title":"Antibody-based vascular tumor targeting","volume":"180","author":"Schliemann","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"10.1002\/art.30650-BIB40|cit40","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.jid.5700653","article-title":"A human mAb specific to oncofetal fibronectin selectively targets chronic skin inflammation in vivo","volume":"127","author":"Trachsel","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1002\/art.30650-BIB41|cit41","doi-asserted-by":"crossref","first-page":"21769","DOI":"10.1074\/jbc.273.34.21769","article-title":"Design and use of a phage display library: human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel","volume":"273","author":"Pini","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1002\/art.30650-BIB42|cit42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1517\/14728222.9.3.491","article-title":"ED-B fibronectin as a target for antibody-based cancer treatments","volume":"9","author":"Menrad","year":"2005","journal-title":"Expert Opin Ther Targets"},{"key":"10.1002\/art.30650-BIB43|cit43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10238-004-0039-y","article-title":"Antibody-cytokine fusion proteins: innovative weapons in the war against cancer","volume":"4","author":"Dela Cruz","year":"2004","journal-title":"Clin Exp Med"},{"key":"10.1002\/art.30650-BIB44|cit44","doi-asserted-by":"crossref","first-page":"R142","DOI":"10.1186\/ar2814","article-title":"Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis","volume":"11","author":"Schwager","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1002\/art.30650-BIB45|cit45","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.yexcr.2009.11.004","article-title":"Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3","volume":"316","author":"Pfaffen","year":"2009","journal-title":"Exp Cell Res"},{"key":"10.1002\/art.30650-BIB46|cit46","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/mabs.1.6.10015","article-title":"Bispecific antibodies for cancer therapy: the light at the end of the tunnel?","volume":"1","author":"Chames","year":"2009","journal-title":"MAbs"},{"key":"10.1002\/art.30650-BIB47|cit47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4161\/mabs.1.2.7631","article-title":"Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LT\u03b2R","volume":"1","author":"Michaelson","year":"2009","journal-title":"MAbs"},{"key":"10.1002\/art.30650-BIB48|cit48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/protein\/gzp073","article-title":"Engineering of stable bispecific antibodies targeting IL-17A and IL-23","volume":"23","author":"Mabry","year":"2010","journal-title":"Protein Eng Des Sel"}],"container-title":["Arthritis & Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.30650","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/art.30650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T21:53:48Z","timestamp":1625090028000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.30650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,29]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1002\/art.30650","relation":{},"ISSN":["0004-3591"],"issn-type":[{"value":"0004-3591","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11,29]]}}}